Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by date.
Page 4: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
901 | 0 | 0 | 993 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
902 | 0 | 0 | 994 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
903 | 0 | 0 | 995 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Jakobezyk-Zmija M; Kaven C; Spraul CW; Lang GK; Lang GE Effect of thalidomide and prednisolone on the secretion of growth factors by human RPE cells in vitro | 0 | 0 |
904 | 0 | 0 | 996 2000 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
905 | 12 | 44 | 1007 2000 MAR [15] JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
906 | 0 | 0 | 1034 2000 MAR [15] ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
907 | 9 | 41 | 1057 2000 MAR [15] TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
908 | 0 | 0 | 869 2000 MAR 26 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 219:U227-U227 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites: Preparation of (+)-2-(N-phthalimido)- 4-hydroxyglutamic acid derivatives. | 0 | 0 |
909 | 1 | 1 | 1031 2000 MAR 30 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-975 Kishi Y; Oki Y; Machida U Thalidomide in multiple myeloma | 3 | 5 |
910 | 1 | 4 | 1032 2000 MAR 30 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-976 Barlogie B Thalidomide in multiple myeloma - Reply | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
911 | 3 | 18 | 1059 2000 APR 1 TETRAHEDRON LETTERS 41(14):2275-2278 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-gamma-hydroxyglutamic acid | 3 | 7 |
912 | 0 | 0 | 1029 2000 APR 11 NEUROLOGY 54(7):A12-A13 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips P A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1) | 0 | 0 |
913 | 62 | 96 | 877 2000 APR 15 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 60 | 103 |
914 | 75 | 113 | 894 2000 APR [15] BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
915 | 8 | 19 | 948 2000 APR [15] BRITISH JOURNAL OF HAEMATOLOGY 109(1):89-96 Juliusson G; Celsing F; Turesson I; Lenhoff S; Adriansson M; Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | 88 | 117 |
916 | 0 | 0 | 970 2000 APR [15] DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
917 | 0 | 0 | 979 2000 APR [15] GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
918 | 0 | 0 | 980 2000 APR [15] GASTROENTEROLOGY 118(4):A582-A582 Kam LY; Vasiliauskas EA; Abreu MT; Hassard PV; Zeldis J; Targan SR Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). | 1 | 6 |
919 | 0 | 0 | 981 2000 APR [15] GASTROENTEROLOGY 118(4):A586-A586 Prehn JL; Muller GW; Man HW; Stirling DJ; Targan SR Thalidomide analogs, but not thalidomide itself, are potent inhibitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-Gamma production in response to T cell stimuli. | 0 | 0 |
920 | 1 | 1 | 1008 2000 APR [15] JOURNAL OF INFECTIOUS DISEASES 181(4):1521-1521 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. (vol 181, pg 954, 2000) | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
921 | 0 | 0 | 1035 2000 APR [15] ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
922 | 0 | 0 | 1046 2000 APR [15] PEDIATRIC RESEARCH 47(4):264A-264A Hanekom W; Ganiso B; Appolis P; Hughes J; Allin R; Goddard E; Haslett P; Hussey G; Kaplan G Safety and immune effects of thalidomide in HIV-infected children | 0 | 0 |
923 | 13 | 41 | 1002 2000 APR 21 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 32 |
924 | 0 | 0 | 966 2000 APR 28 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
925 | 0 | 0 | 978 2000 MAY 11 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
926 | 9 | 60 | 878 2000 MAY [15] AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 3 | 24 |
927 | 12 | 33 | 961 2000 MAY [15] CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
928 | 0 | 0 | 968 2000 MAY [15] DIABETES 49:A434-A434 Iqbal N; Boden G Thalidomide impairs insulin stimulated glucose uptake in patients with type 2 diabetes (T2DM) by inhibiting glycogen synthesis | 0 | 0 |
929 | 2 | 2 | 990 2000 MAY [15] INFLAMMATORY BOWEL DISEASES 6(2):152-153 Katz JA Thalidomide for Crohn's disease: High dose, low dose, or "no doze" at all? Comment | 1 | 1 |
930 | 18 | 27 | 992 2000 MAY [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
931 | 9 | 15 | 1009 2000 MAY [15] JOURNAL OF INFECTIOUS DISEASES 181(5):1813-1816 Juffermans NP; Verbon A; Olszyna DP; van Deventer SJH; Speelman P; van der Poll T Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4(+) T cells in humans | 3 | 5 |
932 | 92 | 148 | 1028 2000 MAY-JUN [MAY 15] NATIONAL MEDICAL JOURNAL OF INDIA 13(3):132-141 Grover JK; Vats V; Gopalakrishna R; Ramam M Thalidomide: A re-look | 2 | 3 |
933 | 16 | 59 | 1047 2000 MAY [15] QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS 93(5):305-311 Davey PP; Ashrafian H New therapies for heart failure: is thalidomide the answer? | 6 | 9 |
934 | 3 | 14 | 874 2000 JUN [15] AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 23(3):319-321 Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide | 14 | 26 |
935 | 85 | 116 | 881 2000 JUN-JUL [JUN 15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(6-7):603-613 Laffitte E; Revuz J Thalidomide | 7 | 9 |
936 | 26 | 174 | 893 2000 JUN 15 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
937 | 2 | 6 | 943 2000 JUN [15] BONE MARROW TRANSPLANTATION 25(12):1319-1320 Zomas A; Anagnostopoulos N; Dimopoulos MA Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent | 18 | 32 |
938 | 17 | 27 | 1015 2000 JUN [15] JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
939 | 18 | 37 | 1061 2000 JUN 15 TOXICOLOGY AND APPLIED PHARMACOLOGY 165(3):237-244 Karrow NA; McCay JA; Brown RD; Musgrove DL; Pettit DA; Munson AE; Germolec DR; White KL Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice | 5 | 8 |
940 | 3 | 13 | 1021 2000 JUN 16 LIFE SCIENCES 67(4):457-461 Thiele A; Thormann M; Hofmann HJ; Naumann WW; Eger K; Hauschildt S A possible role of N-cadherin in thalidomide teratogenicity | 4 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
941 | 0 | 0 | 946 2000 JUL [15] BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
942 | 0 | 0 | 962 2000 JUL [15] CLINICAL INFECTIOUS DISEASES 31(1):312-312 Joyce MP; Sandoval FG; Shannon EJ Thalidomide's effect on immune parameters in untreated lepromatous leprosy and erythema nodosum leprosum | 0 | 0 |
943 | 0 | 0 | 976 2000 JUL [15] EXPERIMENTAL HEMATOLOGY 28(7):103-104 Raza A; Lisak L; Little L; Andrews C; Meyer P; Ekbal M; Venugopal P Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide | 0 | 0 |
944 | 0 | 0 | 977 2000 JUL [15] EXPERIMENTAL HEMATOLOGY 28(7):110-110 Janssen WE; Dalton WS Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide | 0 | 0 |
945 | 2 | 2 | 984 2000 JUL [15] GUT 47(1):156-156 Ryan J Thalidomide treatment of oesophageal ulceration | 0 | 0 |
946 | 13 | 67 | 1004 2000 JUL [15] JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 45 | 83 |
947 | 21 | 40 | 1005 2000 JUL [15] JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 39 | 54 |
948 | 27 | 36 | 1014 2000 JUL [15] JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
949 | 0 | 0 | 1036 2000 JUL [15] ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
950 | 2 | 5 | 1017 2000 AUG 12 LANCET 356(9229):566-567 Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Effect of thalidomide on gastrointestinal toxic effects of irinotecan | 21 | 30 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
951 | 23 | 45 | 952 2000 AUG [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 21 |
952 | 7 | 23 | 969 2000 AUG [15] DIABETES CARE 23(8):1172-1176 Iqbal N; Zayed M; Boden G Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes | 3 | 3 |
953 | 41 | 120 | 971 2000 AUG [15] DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
954 | 0 | 0 | 974 2000 AUG-SEP [AUG 15] EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
955 | 4 | 8 | 982 2000 AUG [15] GASTROENTEROLOGY 119(2):596-596 Fishman SJ; Feins NR; D'Amato RJ; Folkman J Thalidomide therapy for Crohn's disease | 5 | 12 |
956 | 0 | 0 | 983 2000 AUG-SEP [AUG 15] GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
957 | 3 | 20 | 989 2000 AUG [15] INFLAMMATION 24(4):347-356 Lindsay L; Oliver SJ; Freeman SL; Josien R; Krauss A; Kaplan G Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone | 1 | 5 |
958 | 4 | 17 | 1000 2000 AUG [15] JOURNAL OF CHILD NEUROLOGY 15(8):497-503 Schoeman JF; Springer P; Ravenscroft A; Donald PR; Bekker LG; van Rensburg AJ; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role | 8 | 11 |
959 | 8 | 8 | 1010 2000 AUG [15] JOURNAL OF INFECTIOUS DISEASES 182(2):639-639 Gori A; Rossi MC; Trabattoni D; Marchetti G; Fusi ML; Molteni C; Clerici M; Franzetti F Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection | 6 | 7 |
960 | 4 | 5 | 1011 2000 AUG [15] JOURNAL OF INFECTIOUS DISEASES 182(2):640-640 Kaplan G Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection - Reply | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
961 | 7 | 16 | 1022 2000 AUG [15] MAYO CLINIC PROCEEDINGS 75(8):842-844 Federman GL; Federman DG Recalcitrant pyoderma gangrenosum treated with thalidomide | 5 | 13 |
962 | 4 | 5 | 1027 2000 AUG [15] MUSCLE & NERVE 23(8):1301-1302 Rao DG; Kane NM; Oware A Thalidomide neuropathy: Role of F-wave monitoring | 5 | 5 |
963 | 5 | 5 | 872 2000 AUG 18 AIDS 14(12):1859-1861 Gori A; Rossi MC; Marchetti G; Trabattoni D; Molteni C; Cogliati M; Bandera A; Clerici M; Franzetti F Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease | 5 | 7 |
964 | 0 | 0 | 870 2000 AUG 20 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220:U96-U96 Luzzio FA; Thomas EM; Figg WD Thalidomide analogs and metabolites: Cyclic and acyclic derivatives of 2S, 3S-2-N-phthalimido(3-hydroxy)ornithine. | 0 | 0 |
965 | 0 | 0 | 955 2000 AUG 21 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
966 | 17 | 19 | 998 2000 20000821-22:44:17 [AUG 21] JOINT BONE SPINE 67(4):259-261 Wendling D; Toussirot E; Michel F Thalidomide: a comeback? | 1 | 4 |
967 | 7 | 12 | 875 2000 SEP 1 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 57(17):1607-1610 Eriksson T; Wallin R; Hoglund P; Roth B; Qi ZQ; Ostraat O; Bjorkman S Low bioavailability of rectally administered thalidomide | 2 | 2 |
968 | 7 | 25 | 1060 2000 SEP 9 TETRAHEDRON LETTERS 41(37):7151-7155 Luzzio FA; Thomas EM; Figg WD Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine | 4 | 6 |
969 | 13 | 32 | 873 2000 SEP [15] AIDS RESEARCH AND HUMAN RETROVIRUSES 16(14):1345-1355 Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PAJ; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M Thalidomide for the treatment of AIDS-associated wasting | 13 | 28 |
970 | 17 | 32 | 887 2000 SEP [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 17 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
971 | 0 | 0 | 891 2000 SEP [15] ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
972 | 0 | 0 | 892 2000 SEP [15] ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
973 | 4 | 4 | 949 2000 SEP [15] BRITISH JOURNAL OF HAEMATOLOGY 110(3):754-754 Gutheil J; Finucane D Thalidomide therapy in refractory solid tumour patients | 10 | 13 |
974 | 13 | 49 | 958 2000 SEP [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
975 | 15 | 32 | 972 2000 SEP [15] ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 17 |
976 | 8 | 15 | 1012 2000 SEP [15] JOURNAL OF INFECTIOUS DISEASES 182(3):983-987 Lokensgard JR; Hu SX; van Fenema EM; Sheng WS; Peterson PK Effect of thalidomide on chemokine production by human microglia | 8 | 11 |
977 | 10 | 28 | 1023 2000 SEP [15] MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
978 | 2 | 4 | 1045 2000 SEP [15] PALLIATIVE MEDICINE 14(5):429-431 Deaner PB The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report | 0 | 1 |
979 | 1 | 3 | 1058 2000 SEP [15] TERATOLOGY 62(3):172-173 Adams J; Buttar HS; Chambers C; Collins TFX; Graham JM; Jones KL; Kweder S; Mitala J; Polifka JE; Schwetz BA; Public Affairs Comm Teratology society public affairs committee position paper: Thalidomide | 0 | 1 |
980 | 4 | 6 | 1033 2000 SEP 28 NEW ENGLAND JOURNAL OF MEDICINE 343(13):972-973 Rajkumar SV; Gertz MA; Witzig TE Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. | 23 | 33 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
981 | 1 | 5 | 1006 2000 OCT 1 JOURNAL OF CLINICAL ONCOLOGY 18(19):3453-3453 Cohen MH Thalidomide in the treatment of high-grade gliomas | 1 | 3 |
982 | 13 | 22 | 1056 2000 20001011-21:35:04 [OCT 11] TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(5):301-311 Teo S; Morgan M; Stirling D; Thomas S Assessment of the in vitro and in vivo genotoxicity of Thalomid (R) (Thalidomide) | 1 | 1 |
983 | 0 | 0 | 876 2000 OCT [15] AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
984 | 8 | 19 | 944 2000 OCT [15] BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
985 | 20 | 98 | 954 2000 OCT [15] CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
986 | 5 | 15 | 956 2000 OCT [15] CHROMATOGRAPHIA 52(7-8):455-458 Alvarez C; Sanchez-Brunete JA; Torrado-Santiago S; Cadorniga R; Torrado JJ Enantioselective separation of thalidomide on on immobilized alpha(l)-acid glycoprotein chiral stationary phase | 0 | 2 |
987 | 4 | 9 | 985 2000 OCT [15] HAEMATOLOGICA 85(10):1111-1112 Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Low-dose thalidomide in the treatment of refractory myeloma | 11 | 19 |
988 | 0 | 0 | 986 2000 OCT [15] HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
989 | 10 | 31 | 896 2000 NOV 1 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 90 | 173 |
990 | 0 | 0 | 882 2000 20001109-19:09:28 [NOV 09] ANNALS OF ONCOLOGY 11:54-54 Martinelli G; Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
991 | 0 | 0 | 883 2000 20001109-19:09:28 [NOV 09] ANNALS OF ONCOLOGY 11:60-60 Gasparini G; Gilberti S; Vitale S; Arena MG; Fanelli M; Ranieri G; Gattuso D; Biondi E; Morabito A Antitumoral activity of Thalidomide in patients affected by refractory breast cancer nad recurrent high grade gliomas. | 0 | 0 |
992 | 0 | 0 | 884 2000 20001115-18:58:21 [NOV 15] ANNALS OF ONCOLOGY 11:96-96 Galani E; Grigoraki V; Kiamouris C; Samantas E; Economou O; Papdimitriou C; Gika D; Anagnostopoulos N; Dimopoulos M Thalidomide and dexamethasone combination for refractory multiple myeloma. | 0 | 0 |
993 | 0 | 0 | 885 2000 20001115-18:58:21 [NOV 15] ANNALS OF ONCOLOGY 11:96-96 Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F; Martinelli G Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis. | 0 | 0 |
994 | 19 | 38 | 886 2000 NOV [15] ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
995 | 0 | 0 | 959 2000 NOV [15] CLINICAL CANCER RESEARCH 6:4522S-4523S Figg WD; Dahut W; Libutti SK; Carrasquillo J; Bacharach S; Kurdziel K; Huebsch F; Kruger EA; Pluda J; Reed E Thalidomide, an angiogenesis inhibitor, has activity in metastatic prostate cancer. | 0 | 0 |
996 | 13 | 49 | 960 2000 NOV [15] CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
997 | 45 | 95 | 965 2000 NOV [15] CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 41 |
998 | 0 | 0 | 967 2000 NOV [15] DEVELOPMENTAL DYNAMICS 219(3):443-443 Fillmore BJ; Stephens TD Angiogenic integrin avb3 as a site of the teratogenic action of thalidomide | 0 | 0 |
999 | 19 | 40 | 987 2000 NOV [15] HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
1000 | 0 | 0 | 897 2000 NOV 16 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1001 | 0 | 0 | 898 2000 NOV 16 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
1002 | 0 | 0 | 899 2000 NOV 16 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
1003 | 0 | 0 | 900 2000 NOV 16 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
1004 | 0 | 0 | 901 2000 NOV 16 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
1005 | 0 | 0 | 902 2000 NOV 16 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
1006 | 0 | 0 | 903 2000 NOV 16 BLOOD 96(11):168A-168A Kropff MH; Innig G; Mitterer M; Straka C; Ostermann H; Koch OM; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. | 0 | 7 |
1007 | 0 | 0 | 904 2000 NOV 16 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
1008 | 0 | 0 | 905 2000 NOV 16 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
1009 | 0 | 0 | 906 2000 NOV 16 BLOOD 96(11):168A-169A Raza SN; Veksler Y; Sabir T; Li ZJ; Anderson L; Jagannath S Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). | 0 | 7 |
1010 | 0 | 0 | 907 2000 NOV 16 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1011 | 0 | 0 | 908 2000 NOV 16 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
1012 | 0 | 0 | 909 2000 NOV 16 BLOOD 96(11):261B-261B Lisak LA; Little L; Dean L; Ekbal M; duRandt M; Hussain M; Kaistha V; Raza A Delayed responses to thalidomide in patients with myelodysplastic syndromes. | 0 | 0 |
1013 | 0 | 0 | 910 2000 NOV 16 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
1014 | 0 | 0 | 911 2000 NOV 16 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
1015 | 0 | 0 | 912 2000 NOV 16 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
1016 | 0 | 0 | 913 2000 NOV 16 BLOOD 96(11):288B-288B Gibson RK; Alley L; Shuman HW Thalidomide (Thal) monotherapy is effective in previously treated recurrent multiple myeloma (MM). | 0 | 0 |
1017 | 0 | 0 | 914 2000 NOV 16 BLOOD 96(11):289B-289B Kakimoto T; Hattori Y; Okamoto S; Kamata T; Satoh N; Takayama N; Matsushita H; Yamada T; Du WL; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma. Decreased plasma concentration of angiogenic growth factors and clinical response. | 0 | 0 |
1018 | 0 | 0 | 915 2000 NOV 16 BLOOD 96(11):290B-290B Moehler TM; Neben K; Hawighorst H; Egerer G; van Kaick G; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. | 0 | 5 |
1019 | 0 | 0 | 916 2000 NOV 16 BLOOD 96(11):290B-290B Linder O; Tidefelt U Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? | 0 | 0 |
1020 | 0 | 0 | 917 2000 NOV 16 BLOOD 96(11):290B-290B Leleu X; Cornillon J; Magro L; Guillerm G; Dalle JH; Fenaux P; Jouet JP; Bauters F; Facon T; Yakoub-Agha I Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma? | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1021 | 0 | 0 | 918 2000 NOV 16 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
1022 | 0 | 0 | 919 2000 NOV 16 BLOOD 96(11):293B-293B Prince HM; Biagi JJ; Mitchell P; Mileshkin L; Seymour JF; Januszewicz EH; Wolf MM; Westerman DA Interferon-alpha-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM). | 0 | 3 |
1023 | 0 | 0 | 920 2000 NOV 16 BLOOD 96(11):294B-294B Rodriguez J; Oyama Y; Burt RK; Traynor AE Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance. | 0 | 4 |
1024 | 0 | 0 | 921 2000 NOV 16 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
1025 | 0 | 0 | 922 2000 NOV 16 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
1026 | 0 | 0 | 923 2000 NOV 16 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
1027 | 0 | 0 | 924 2000 NOV 16 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
1028 | 0 | 0 | 925 2000 NOV 16 BLOOD 96(11):304A-304A Hideshima T; Chauhan D; Shima Y; Noopur R; Davies FE; Tai YT; Treon SP; Lin BK; Schlossman RL; Richardson PG; Gupta D; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. | 0 | 0 |
1029 | 0 | 0 | 926 2000 NOV 16 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
1030 | 0 | 0 | 927 2000 NOV 16 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1031 | 0 | 0 | 928 2000 NOV 16 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
1032 | 0 | 0 | 929 2000 NOV 16 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
1033 | 0 | 0 | 930 2000 NOV 16 BLOOD 96(11):364A-364A Rajkumar SV; Timm M; Mesa RA; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Gertz MA; Kyle RA; Griepp PR; Witzig TE Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. | 0 | 5 |
1034 | 0 | 0 | 931 2000 NOV 16 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
1035 | 0 | 0 | 932 2000 NOV 16 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
1036 | 0 | 0 | 933 2000 NOV 16 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
1037 | 0 | 0 | 934 2000 NOV 16 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
1038 | 0 | 0 | 935 2000 NOV 16 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
1039 | 0 | 0 | 936 2000 NOV 16 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
1040 | 0 | 0 | 937 2000 NOV 16 BLOOD 96(11):579A-+ Lentzsch S; Podar K; Davies FE; Hideshima T; Tai YT; Chauhan D; Lin BK; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Muller GW; Stirling DI; Anderson KC Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1041 | 0 | 0 | 938 2000 NOV 16 BLOOD 96(11):746A-746A Piccaluga PP; Finelli C; Ricci P; Cavo M; Pileri SA; Isidori A; Malagola M; Grafone T; Tura S; Visani G Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleucocytosis, splenomegaly in idiopathic myelofibrosis. | 0 | 4 |
1042 | 0 | 0 | 939 2000 NOV 16 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
1043 | 0 | 0 | 940 2000 NOV 16 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
1044 | 4 | 10 | 1024 2000 20001127-20:19:24 [NOV 27] MEDICINA-BUENOS AIRES 60:61-65 Politi PM Thalidomide. Clinical trials in cancer. | 1 | 1 |
1045 | 4 | 8 | 941 2000 DEC 1 BLOOD 96(12):3995-3996 Koc S; Leisenring W; Flowers MED; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ Thalidomide for treatment of patients with chronic graft-versus-host disease | 14 | 23 |
1046 | 1 | 3 | 942 2000 DEC 1 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 24 |
1047 | 8 | 38 | 1043 2000 DEC 1 PAIN 88(3):267-275 George A; Marziniak M; Schafers M; Toyka KV; Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin | 4 | 21 |
1048 | 4 | 4 | 888 2000 DEC [15] ARCHIVES OF DERMATOLOGY 136(12):1442-1443 Camisa C; Popovsky JL Effective treatment of oral erosive lichen planus with thalidomide | 6 | 11 |
1049 | 1 | 1 | 950 2000 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 111(3):986-986 Myers B; Crouch D; Dolan G Thalidomide treatment in advanced refractory myeloma | 5 | 5 |
1050 | 7 | 20 | 973 2000 DEC [15] EUROPEAN CYTOKINE NETWORK 11(4):574-579 van Crevel R; Vonk AG; Netea MG; Kullberg BJ; van der Meer JWM Modulation of LPS-, PHA-and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1051 | 1 | 1 | 1001 2000 DEC [15] JOURNAL OF CHILD NEUROLOGY 15(12):838-838 Schoeman JF Thalidomide therapy in childhood tuberculous meningitis | 3 | 4 |
1052 | 15 | 19 | 1018 2000 DEC [15] LEPROSY REVIEW 71:S117-S120 Kaplan G Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions | 1 | 2 |
1053 | 0 | 0 | 1019 2000 DEC [15] LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
1054 | 0 | 0 | 1025 2000 DEC [15] MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
1055 | 0 | 0 | 1026 2000 DEC [15] MOLECULAR BIOLOGY OF THE CELL 11:452A-452A Ezell TN; Odoms S; Davis M; Taylor L Human T leukemic cells exhibit biochemical changes consistent with apoptosis after treatment with tumor necrosis factor alpha and thalidomide. | 0 | 0 |
1056 | 0 | 0 | 1037 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):9-10 Rajkumar SV Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction | 2 | 2 |
1057 | 12 | 57 | 1038 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
1058 | 4 | 12 | 1039 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
1059 | 7 | 16 | 1040 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):25-28 Hwu WJ New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide | 6 | 14 |
1060 | 2 | 8 | 1041 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):29-32 Govindarajan R Irinotecan and thalidomide in metastatic colorectal cancer | 7 | 12 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1061 | 7 | 18 | 1042 2000 DEC [15] ONCOLOGY-NEW YORK 14(12):33-36 Amato R Thalidomide for recurrent renal-cell cancer in a 40-year-old man | 2 | 2 |
1062 | 1 | 1 | 1069 2001 JAN [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(1):87-87 Schmutz JL; Barbaud A; Trechot P Buccal lichen after thalidomide | 0 | 0 |
1063 | 4 | 4 | 1144 2001 JAN [15] BONE MARROW TRANSPLANTATION 27(2):229-230 Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K Severe cutaneous ulceration following treatment with thalidomide for GVHD | 0 | 1 |
1064 | 92 | 115 | 1177 2001 JAN [15] DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
1065 | 16 | 47 | 1185 2001 JAN [15] DRUGS OF THE FUTURE 26(1):100-103 [Anon] Thalidomide - Synovir (R) - Thalomid (R) - Talizer (R) - Oncolytic treatment of IBD antiarthritic treatment of leprosy | 0 | 0 |
1066 | 13 | 23 | 1213 2001 JAN [15] INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
1067 | 4 | 10 | 1228 2001 JAN 15 JOURNAL OF INFECTIOUS DISEASES 183(2):343-346 Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C; Natl Inst Allergy Infect Dis AIDS Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers | 1 | 3 |
1068 | 9 | 23 | 1230 2001 JAN [15] JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 12 | 22 |
1069 | 6 | 15 | 1258 2001 JAN-FEB [JAN 15] OPHTHALMOLOGICA 215(1):70-73 Parentin F; Da Pozzo S; Lepore L; Perissutti P Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child | 2 | 2 |
1070 | 13 | 18 | 1265 2001 JAN [15] REVUE DE MEDECINE INTERNE 22(1):5-7 Grosbois B; Duguet C Thalidomide: the revival | 2 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1071 | 23 | 52 | 1278 2001 JAN [15] TOXICOLOGICAL SCIENCES 59(1):160-168 Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs | 5 | 5 |
1072 | 5 | 7 | 1267 2001 JAN 22 SCIENTIST 15(2):1-+ Lewis R The return of thalidomide | 0 | 1 |
1073 | 3 | 7 | 1070 2001 FEB [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(2):148-149 Esteve E; Legac E Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide | 4 | 4 |
1074 | 6 | 12 | 1148 2001 FEB [15] BRITISH JOURNAL OF DERMATOLOGY 144(2):227-228 Allen BR Thalidomide | 4 | 4 |
1075 | 24 | 32 | 1149 2001 FEB [15] BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
1076 | 10 | 18 | 1233 2001 FEB [15] JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181 Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results | 10 | 17 |
1077 | 10 | 51 | 1163 2001 FEB 26 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
1078 | 0 | 0 | 1190 2001 MAR 7 FASEB JOURNAL 15(4):A556-A556 Jajeh A; Boulos B; Youakim J; Ali M; Woynarowsky A In vitro reduction of accelerated apoptosis of neutrophils in blood drawn from an HIV positive subject with Thalidomide. | 0 | 0 |
1079 | 44 | 140 | 1183 2001 20010309-15:04:09 [MAR 09] DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 14 |
1080 | 3 | 4 | 1276 2001 MAR 10 SWISS MEDICAL WEEKLY 131(9-10):133-133 Trojan A; Anagnostara A; Fost L Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1081 | 0 | 0 | 1143 2001 MAR [15] BONE MARROW TRANSPLANTATION 27:S251-S252 Hus M; Dmoszynska A; Legiec W; Jawniak D; Soroka-Wojtaszko M; Manko J Thalidomide as a preparative regimen and late stem cell transplantation in patients with relapsed or refractory multiple myeloma | 0 | 0 |
1082 | 0 | 0 | 1196 2001 MAR [15] GUT 48:A48-A48 Khan ZH; Cole AT; Macdonald I; Pye D; Simpson L; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancer | 0 | 0 |
1083 | 0 | 0 | 1197 2001 MAR [15] GUT 48:A67-A68 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
1084 | 0 | 0 | 1198 2001 MAR [15] GUT 48:A89-A90 Trebble T; Johns T; Duncan HD; Goggin PM An open trial of thalidomide in refractory Crohn's colitis | 0 | 0 |
1085 | 0 | 0 | 1215 2001 MAR 15 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42(4):S233-S233 Maguire MG; Fine SL; Maguire AM; D'Amato RJ; Singerman LJ Results of the age-related macular degeneration and thalidomide study (AMDATS). | 0 | 5 |
1086 | 24 | 28 | 1234 2001 MAR [15] JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
1087 | 0 | 0 | 1238 2001 MAR [15] LEUKEMIA 15(3):491-491 Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 0 |
1088 | 0 | 0 | 1252 2001 MAR [15] ONCOLOGY-NEW YORK 15(3):301-301 [Anon] Thalidomide analogs active against multiple myeloma | 0 | 0 |
1089 | 8 | 16 | 1260 2001 MAR-APR [MAR 15] PEDIATRIC DERMATOLOGY 18(2):143-145 Brik R; Shamali H; Bergman R Successful thalidomide treatment of severe infantile Behcet disease | 1 | 1 |
1090 | 0 | 1 | 1245 2001 MAR 22 NATURE 410(6827):411-412 Dormandy T Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1091 | 4 | 7 | 1065 2001 APR [15] AMERICAN JOURNAL OF GASTROENTEROLOGY 96(4):1305-1306 Ginsburg PM; Hanan I; Ehrenpreis ED Treatment of severe esophageal Crohn's disease with thalidomide | 8 | 10 |
1092 | 7 | 12 | 1067 2001 APR [15] AMERICAN JOURNAL OF HEMATOLOGY 66(4):300-302 Fowler R; Imrie K Thalidomide-associated hepatitis: A case report | 5 | 6 |
1093 | 14 | 32 | 1090 2001 APR [15] BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
1094 | 2 | 4 | 1092 2001 APR 15 BLOOD 97(8):2527-2528 Kyrtsonis MC; Kokoris SI; Kontopidou FN; Siakantaris MP; Kittas C; Pangalis GA Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody | 0 | 1 |
1095 | 7 | 37 | 1161 2001 APR [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(4):319-326 Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac | 2 | 10 |
1096 | 0 | 0 | 1192 2001 APR [15] GASTROENTEROLOGY 120(5):A278-A278 Stein DJ; Rafiee P; Taras A; Lamirand TH; Fisher PJ; Ogawa H; Telford GL; Otterson MF; Johnson CP; Binion DG Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). | 0 | 0 |
1097 | 0 | 0 | 1193 2001 APR [15] GASTROENTEROLOGY 120(5):A611-A612 Khan ZH; Cole AT; MacDonald I; Pye D; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancers | 0 | 0 |
1098 | 0 | 2 | 1199 2001 APR [15] HAEMATOLOGICA 86(4):348-348 [Anon] Thalidomide in the treatment of multiple myeloma | 0 | 0 |
1099 | 7 | 27 | 1200 2001 APR [15] HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 25 | 38 |
1100 | 5 | 21 | 1201 2001 APR [15] HAEMATOLOGICA 86(4):404-408 Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp Thalidomide treatment of resistant or relapsed multiple myeloma patients | 23 | 35 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1101 | 17 | 33 | 1202 2001 APR [15] HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
1102 | 0 | 0 | 1203 2001 APR [15] HAEMATOLOGICA 86(4):448-448 Zappasodi P; Lorenzi A; Corso A Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity | 1 | 1 |
1103 | 18 | 36 | 1212 2001 APR [15] INFLAMMATION 25(2):91-96 Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP Differential effects of thalidomide on angiogenesis and tumor growth in mice | 0 | 2 |
1104 | 0 | 0 | 1227 2001 APR [15] JOURNAL OF HEPATOLOGY 34:18-18 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
1105 | 0 | 1 | 1241 2001 APR 15 LIBRARY JOURNAL 126(7):126-126 Kupferberg N Dark remedy: The impact of thalidomide and its revival as a vital medicine. | 0 | 0 |
1106 | 0 | 0 | 1253 2001 APR [15] ONCOLOGY-NEW YORK 15(4):493-+ [Anon] Thalidomide studied in a variety of cancers and metabolic disorders | 0 | 0 |
1107 | 0 | 0 | 1247 2001 APR 24 NEUROLOGY 56(8):A208-A209 Khella SL; Souayah N; AMDATS Study Grp Thalidomide polyneuropathy: A prospective double-masked placebo-controlled study in an elderly population with age-related macular degeneration | 0 | 0 |
1108 | 29 | 42 | 1242 2001 20010503-14:08:37 [MAY 03] LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
1109 | 32 | 44 | 1068 2001 MAY [15] AMERICAN JOURNAL OF THE MEDICAL SCIENCES 321(5):321-326 Moraes M; Russo G Thalidomide and its dermatologic uses | 3 | 9 |
1110 | 11 | 12 | 1071 2001 MAY [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(5):611-613 Estines O; Revuz J; Wolkenstein P; Bressieux JM; Roujeau JC; Cosnes A Sarcoidosis: thalidomide treatment in ten patients | 5 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1111 | 5 | 14 | 1077 2001 MAY [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 45(5):1547-1549 Juffermans NP; Verbon A; Schultz MJ; Hack CE; van Deventer SJH; Speelman P; van der Poll T Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens | 2 | 2 |
1112 | 1 | 33 | 1089 2001 MAY [15] BIOMEDICAL CHROMATOGRAPHY 15(3):202-206 Duval R; Leveque H; Prigent Y; Aboul-Enein HY Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases | 1 | 4 |
1113 | 13 | 41 | 1091 2001 MAY [15] BIOORGANIC & MEDICINAL CHEMISTRY 9(5):1279-1291 Hess S; Akermann MA; Wnendt S; Zwingerberger K; Eger K Synthesis and immunological activity of water-soluble thalidomide prodrugs | 2 | 4 |
1114 | 5 | 12 | 1151 2001 MAY [15] BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
1115 | 3 | 10 | 1166 2001 MAY [15] CHILDS NERVOUS SYSTEM 17(6):370-372 Schoeman JF; Ravenscroft A; Hartzenberg HB Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess | 5 | 5 |
1116 | 3 | 3 | 1169 2001 MAY-JUN [MAY 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 19(3):360-361 Scoville CD Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis | 5 | 5 |
1117 | 6 | 6 | 1194 2001 MAY [15] GASTROENTEROLOGY 120(6):1567-1568 Fox MR; Harris A Intractable insomnia after cessation of treatment with thalidomide | 3 | 3 |
1118 | 1 | 26 | 1248 2001 MAY-JUN [MAY 15] NEUROTOXICOLOGY AND TERATOLOGY 23(3):255-264 Vorhees CV; Weisenburger WP; Minck DR Neurobehavioral teratogenic effects of thalidomide in rats | 1 | 3 |
1119 | 50 | 73 | 1086 2001 20010517-08:31:18 [MAY 17] BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
1120 | 0 | 1 | 1251 2001 MAY 17 NEW YORK REVIEW OF BOOKS 48(8):12-15 Horton R Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1121 | 2 | 3 | 1262 2001 JUN 9 PRESSE MEDICALE 30(20):1008-1009 Pouaha J; Martin S; Trechot P; Truchetet F; Barbaud A; Schmutz JL Thalidomide and thrombosis: three cases | 5 | 5 |
1122 | 44 | 67 | 1184 2001 20010613-11:16:17 [JUN 13] DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
1123 | 7 | 31 | 1162 2001 JUN [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
1124 | 0 | 0 | 1175 2001 JUN [15] CLINICAL LYMPHOMA 2(1):16-17 [Anon] Thalidomide shows promise in previously untreated and refractory multiple myeloma | 0 | 0 |
1125 | 0 | 0 | 1180 2001 JUN [15] DIABETES 50:A473-A473 Bosco A; Lerario AC; Santos RF; Ferreira A; Ursich MJ; Silva ME; Rocha DM; Wajchenberg BL Study of Thalidomide and Rosiglitazone effects on the prevention of diabetic retinopathy of Streptozotocin diabetic rats | 0 | 0 |
1126 | 1 | 5 | 1220 2001 JUN [15] JOURNAL OF CHEMICAL EDUCATION 78(6):759-761 Bennett N; Cornely K Thalidomide makes a comeback: A case discussion exercise that integrates biochemistry and organic chemistry | 0 | 3 |
1127 | 20 | 32 | 1224 2001 JUN [15] JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
1128 | 6 | 27 | 1277 2001 JUN [15] SYNTHESIS-STUTTGART (7):999-1000 Seijas JA; Vazquez-Tato MP; Gonzalez-Bande C; Martinez MM; Pacios-Lopez B Microwave promoted synthesis of a rehabilitated drug: Thalidomide | 0 | 2 |
1129 | 4 | 18 | 1088 2001 20010619-07:14:11 [JUN 19] BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
1130 | 3 | 4 | 1249 2001 JUN 21 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952 Osman K; Comenzo R; Rajkumar SV Deep venous thrombosis and thalidomide therapy for multiple myeloma. | 46 | 59 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1131 | 4 | 4 | 1150 2001 20010622-13:09:00 [JUN 22] BRITISH JOURNAL OF DERMATOLOGY 144(6):1292-1293 Passeron T; Lacour JP; Murr D; Ortonne JP Thalidomide-induced amenorrhoea: two cases | 4 | 4 |
1132 | 27 | 53 | 1219 2001 JUN 22 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 33 | 57 |
1133 | 9 | 18 | 1093 2001 JUL 1 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 50 | 94 |
1134 | 21 | 30 | 1073 2001 JUL [15] ANNALS OF ONCOLOGY 12(7):885-886 Thomas DA; Kantarjian HM The revitalization of thalidomide | 4 | 5 |
1135 | 6 | 16 | 1074 2001 JUL [15] ANNALS OF ONCOLOGY 12(7):987-990 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cineri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers | 16 | 27 |
1136 | 5 | 13 | 1075 2001 JUL [15] ANNALS OF ONCOLOGY 12(7):991-995 Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N Thalidomide and dexamethasone combination for refractory multiple myeloma | 30 | 41 |
1137 | 9 | 21 | 1094 2001 JUL 15 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 68 | 113 |
1138 | 2 | 4 | 1146 2001 JUL [15] BRITISH JOURNAL OF CANCER 85:25-25 Dalgleish A; Marriott J; Czajka A; Clarke I; Dredge K; Muller G; Stirling D New thalidomide analogues; Anti-cancer, anti-angiogenic and immunostimulatory. | 0 | 0 |
1139 | 12 | 22 | 1152 2001 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 13 | 24 |
1140 | 1 | 3 | 1153 2001 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 114(1):245-245 Myers B; Grimley C; Dolan G Thalidomide and low-dose dexamethasone in myeloma treatment | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1141 | 4 | 17 | 1170 2001 JUL [15] CLINICAL CANCER RESEARCH 7(7):1888-1893 Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Kruger EA; Gubish E; Pluda JM; Reed E A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer | 25 | 60 |
1142 | 40 | 53 | 1189 2001 JUL [15] EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 12 | 16 |
1143 | 2 | 9 | 1204 2001 JUL [15] HAEMATOLOGICA 86(7):772-773 Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia | 7 | 11 |
1144 | 28 | 70 | 1254 2001 JUL [15] ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
1145 | 4 | 8 | 1255 2001 JUL [15] ONCOLOGY-NEW YORK 15(7):877-878 Govindarajan R Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
1146 | 2 | 8 | 1256 2001 JUL [15] ONCOLOGY-NEW YORK 15(7):878-879 Hwu WJ Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
1147 | 7 | 40 | 1259 2001 JUL-AUG [JUL 15] OPHTHALMOLOGICA 215(4):284-289 Kaven C; Spraul CW; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro | 2 | 7 |
1148 | 6 | 48 | 1268 2001 JUL [15] SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
1149 | 0 | 0 | 1062 2001 AUG [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U653-U653 Shi JD; Xiao ZL; Marks M; Kamat C; Pokala V Development of thalidomide analogs as anti-angiogenic agents. | 0 | 0 |
1150 | 0 | 0 | 1063 2001 AUG [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U659-U659 Xiao ZL; Schaefer K; Li PK Solid phase synthesis of thalidomide and its analogs. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1151 | 0 | 0 | 1064 2001 AUG [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U685-U685 Luzzio FA; Figg WD; Mayorov AV; Kruger EA Thalidomide metabolites and analogs, part 3: Synthesis and antiangiogenic activity of the teratogenic and TNF-alpha-modulatory thalidomide analog EM-12. | 0 | 0 |
1152 | 12 | 59 | 1095 2001 AUG 15 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 29 | 64 |
1153 | 8 | 38 | 1159 2001 AUG [15] BRITISH JOURNAL OF PHARMACOLOGY 133(8):1414-1423 Lienenluke B; Stojanovic T; Fiebig T; Fayyazi A; Germann T; Hecker M Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat-role of endothelial cell-leukocyte interaction | 3 | 4 |
1154 | 59 | 87 | 1188 2001 AUG [15] EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
1155 | 48 | 68 | 1208 2001 AUG [15] HAUTARZT 52(8):726-733 Kuhn A; Hefter H; Ruzicka T; Lehmann P Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus | 0 | 0 |
1156 | 18 | 26 | 1222 2001 AUG 15 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595 Rajkumar SV; Kyle RA Thalidomide in the treatment of plasma cell malignancies | 6 | 7 |
1157 | 7 | 22 | 1223 2001 AUG 15 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601 Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P Treatment of Waldenstrom's macroglobulinemia with thalidomide | 17 | 28 |
1158 | 7 | 29 | 1231 2001 AUG [15] JOURNAL OF NEURO-ONCOLOGY 54(1):31-38 Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme | 15 | 22 |
1159 | 10 | 19 | 1239 2001 AUG [15] LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
1160 | 8 | 17 | 1240 2001 AUG [15] LEUKEMIA & LYMPHOMA 42(4):683-+ Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma | 8 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1161 | 13 | 29 | 1244 2001 AUG [15] MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 12 | 17 |
1162 | 11 | 21 | 1246 2001 AUG [15] NETHERLANDS JOURNAL OF MEDICINE 59(2):45-49 van de Poel MHW; Pasman PC; Schouten HC The use of thalidomide in chronic refractory graft versus host disease | 1 | 3 |
1163 | 11 | 41 | 1266 2001 AUG [15] RHEUMATOLOGY 40(8):933-938 Kari JA; Shah V; Dillon MJ Behcet's disease in UK children: clinical features and treatment including thalidomide | 5 | 16 |
1164 | 8 | 40 | 1269 2001 AUG [15] SEMINARS IN ONCOLOGY 28(4):62-66 Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | 16 | 38 |
1165 | 0 | 0 | 1217 2001 AUG 22 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 286(8):909-909 Mitka M Thalidomide battles myeloma | 1 | 0 |
1166 | 3 | 5 | 1096 2001 SEP 1 BLOOD 98(5):1614-1615 Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy | 63 | 94 |
1167 | 1 | 1 | 1076 2001 SEP [15] ANNALS OF ONCOLOGY 12(9):1333-1333 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001) | 0 | 1 |
1168 | 0 | 0 | 1079 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S125-S125 Barthel HR Successful treatment of Weber Christian disease (WCD) with thalidomide in a patient failing multiple other medical therapies | 0 | 0 |
1169 | 0 | 0 | 1080 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S272-S272 Lehman TJ; Striegel KH; Onel KB Thalidomide therapy for corticosteroid dependent systemic onset juvenile rheumatoid arthritis | 0 | 1 |
1170 | 0 | 0 | 1081 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S275-S275 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis (AS). | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1171 | 0 | 0 | 1082 2001 SEP [15] ARTHRITIS AND RHEUMATISM 44(9):S280-S280 Cuadrado MJ; Smith E; Gordon P; Karim Y; Khamashta MA; Hughes GRV Thalidomide: Efficacy and safety in 30 patients with lupus and skin involvement. | 0 | 0 |
1172 | 12 | 35 | 1171 2001 SEP [15] CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
1173 | 26 | 123 | 1176 2001 SEP [15] CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
1174 | 7 | 46 | 1186 2001 SEP [15] ELECTROPHORESIS 22(15):3185-3190 Schoetz G; Trapp O; Schurig V Determination of the enantiomerization barrier of thalidomide by dynamic capillary electrokinetic chromatography | 1 | 4 |
1175 | 1 | 1 | 1195 2001 SEP [15] GASTROENTEROLOGY 121(3):747-747 Fox MR; Harris A Intractable insomnia after cessation of treatment with Thalidomide. (vol 120, pg 1567, 2001) | 0 | 0 |
1176 | 12 | 25 | 1216 2001 SEP [15] ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648 Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R Amelioration of experimental colitis by thalidomide | 1 | 1 |
1177 | 10 | 27 | 1221 2001 SEP [15] JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364 Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues | 3 | 4 |
1178 | 9 | 9 | 1226 2001 SEP [15] JOURNAL OF DERMATOLOGICAL TREATMENT 12(3):145-147 Thomson KF; Goodfield MJD Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus | 0 | 2 |
1179 | 8 | 27 | 1235 2001 SEP [15] JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226 Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial | 1 | 7 |
1180 | 23 | 55 | 1257 2001 SEP-OCT [SEP 15] OPHTHALMIC RESEARCH 33(5):256-263 Baatz H; Tonessen B; Prada J; Pleyer U Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis | 1 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1181 | 20 | 48 | 1263 2001 SEP-OCT [SEP 15] QUIMICA NOVA 24(5):683-688 Lima LM; Fraga CAM; Barreiro EJ The rebirth of a drug: Thalidomide | 0 | 1 |
1182 | 16 | 37 | 1147 2001 SEP 28 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 19 | 31 |
1183 | 6 | 6 | 1083 2001 OCT [15] ARTHRITIS AND RHEUMATISM 44(10):2456-2457 Lee L; Lawford R; McNeil HP The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: comment on the letter by Breban et al | 2 | 5 |
1184 | 1 | 4 | 1084 2001 OCT [15] ARTHRITIS AND RHEUMATISM 44(10):2457-2458 Breban M; Dougados M The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: Reply | 2 | 5 |
1185 | 2 | 23 | 1085 2001 OCT 15 BIOCHEMICAL PHARMACOLOGY 62(8):1081-1086 Onat D; Stahl W; Sies H Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344) | 2 | 3 |
1186 | 3 | 4 | 1154 2001 OCT [15] BRITISH JOURNAL OF HAEMATOLOGY 115(1):234-234 Myers B; Grimley C; Crouch D; Dolan G Lack of response to thalidomide in plasmacytomas | 2 | 4 |
1187 | 8 | 13 | 1182 2001 OCT [15] DRUG METABOLISM AND DISPOSITION 29(10):1355-1357 Teo SK; Harden JL; Burke AB; Noormohamed FH; Youle M; Johnson MA; Peters BS; Stirling DI; Thomas SD Thalidomide is distributed into human semen after oral dosing | 8 | 13 |
1188 | 8 | 10 | 1205 2001 OCT [15] HAEMATOLOGICA 86(10):1108-1109 Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M Thalidomide and thrombosis in patients with multiple myeloma | 11 | 12 |
1189 | 5 | 20 | 1206 2001 OCT [15] HAUTARZT 52:962-965 Hoch O; Muller S; Buttner G; Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 3 | 5 |
1190 | 3 | 15 | 1207 2001 OCT [15] HAUTARZT 52:966-969 Petering H; Kiehl P; Vogelbruch M; Sticht-Groh V; Kapp A; Werfel T Chemotherapy-induced erythema nodosum leprosum: successful treatment with thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1191 | 0 | 0 | 1209 2001 OCT [15] HEPATOLOGY 34(4):279A-279A Muriel P; Fernandez-Martinez E; Perez-Alvarez VM; Morales-Rios MS A thalidomide analog with hepatoprotective and antifibrotic properties in biliary obstruction-induced cirrhosis in the rat. | 0 | 0 |
1192 | 0 | 0 | 1210 2001 OCT [15] HEPATOLOGY 34(4):516A-516A Muriel P; Ponce S; Garcia JC Thalidomide partially prevents CCl4-induced liver cirrhosis. | 0 | 0 |
1193 | 0 | 0 | 1211 2001 OCT [15] HEPATOLOGY 34(4):517A-517A Muriel P; Garcia JC; Ponce S; Perez-Alvarez VM; Fernandez-Martinez E; Morales-Rios MS Synthesis and pharmacological evaluation of a thalidomide analog, the 3-phthalimido-3-(3,4-dimethoxyphenyl)propanoic acid in liver cirrhosis induced by bile duct ligation in the rat. | 0 | 0 |
1194 | 11 | 18 | 1225 2001 OCT [15] JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097 Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 | 6 | 7 |
1195 | 4 | 29 | 1232 2001 OCT [15] JOURNAL OF NEURO-ONCOLOGY 55(1):11-17 Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S Gliomatosis cerebri: Post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide | 0 | 4 |
1196 | 0 | 5 | 1237 2001 OCT [15] LANCET ONCOLOGY 2(10):634-635 Hwu WJ; Raizer J; Panageas KS; Lis E Treatment of metastatic melanoma in the brain with temozolomide and thalidomide | 3 | 7 |
1197 | 3 | 3 | 1250 2001 OCT 18 NEW ENGLAND JOURNAL OF MEDICINE 345(16):1214-1215 Kudva GC; Collins BT; Dunphy FR Thalidomide for malignant melanoma. | 1 | 2 |
1198 | 30 | 49 | 1178 2001 OCT 19 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
1199 | 3 | 26 | 1179 2001 OCT 19 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1183-1186 Maio G On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation | 0 | 3 |
1200 | 0 | 0 | 1167 2001 OCT 23 CIRCULATION 104(17):123-123 Yang E; Matcuk G; Zhang Y; Talbi S; Chen M; Ho M; Liao C; Tsao PS; Quertermous T; Deng D; Sampas N; Ach R; Love W Anti-angiogenic effects of thalidomide characterized by transciptional profiling of endothelial cell-specific gene expression | 0 | 0 |